What Is MiNK Therapeutics, Inc. (INKT) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, MiNK Therapeutics, Inc.'s intrinsic value is estimated at a composite fair value of $7.81. Trading at $11.09, the stock is approaching fair value or slight overvaluation (implied return of -29.5%), as 6 of 9 models suggest limited further upside. Notably, First Chicago sees the most upside at +53.7% (fair value: $17.04), while ML-RIV is the most conservative at -88.2% ($1.31). The spread between these extremes — +141.9% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About INKT?
9 of 13 models are currently active for INKT. Of these, 3 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates INKT's intrinsic value at $4.28, implying -61.4% downside from the current price. See which stocks rank higher →
How Does INKT Rank in Biological Products, (No Diagnostic Substances)?
Among 134 Biological Products, (No Diagnostic Substances) stocks, INKT ranks #105 by Quality of Company score. CirclFi's QOC score of 4.3/10 evaluates 32 fundamental signals. A score of 4.3 reflects mixed fundamentals.
See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →
MiNK Therapeutics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is INKT a Value Trap?
CirclFi's Value Trap algorithm assigns INKT a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for MiNK Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, MiNK Therapeutics, Inc. scores 4.3 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +141.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every INKT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across INKT's 9 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad